Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca, Merck Sharp & Dohme LLC, and Sanofi
Description:
Prostate cancer is the most diagnosed non-cutaneous cancer in men in
the United States (US) and remains the second leading cause of
cancer deaths among American men, with an estimated 248,530 new
cases diagnosed last year. Prostate cancer deaths are typically the
result of castration-resistant prostate cancer (CRPC), and most
patients will eventually experience disease progression despite
castration, with a median duration of response of 12–24 months.
About 40 percent of these patients have prostate cancer that is also
associated with a rising prostate-specific antigen (PSA) level that
has not spread to other parts of the body. The danger that can
occur, if not caught early, is that 33% of those men could have the
cancer spread to other parts of the body. With guidelines continuing
to be updated, the novel insights in the current and emerging
therapeutic agents hope to continue to improve patient prognosis and
quality of life by delaying metastatic spread and the need for
highly toxic chemotherapeutic agents. Advances in the past few years
have resulted in the investigations of several novel targeted
therapies, including androgen receptor inhibitor (ARI) targeting
agents, antineoplastic agent and gonadotropin releasing hormone
agonist, tyrosine kinase inhibitors (TKIs), antiangiogenic agents,
endothelin receptor antagonists, anti-apoptotic protein inhibitors,
and PARP-1 inhibitors. This session will provide participants with
education on the advances in the treatment and management of
prostate cancer. In the last few years, advances in the treatment of
prostate cancer have greatly improved with new updates in current
and emerging treatments.
Upon completion of this
activity, participants will be able to:
-
Implement guideline-recommended
management strategies for patients with prostate cancer
-
Discuss current diagnostic methods
that will properly identify prostate cancer patients, including
genetic testing guidelines to determine appropriate patient
selection for optimal management
-
Evaluate the latest safety and
efficacy data on current and emerging therapies for prostate
cancer
-
Explore recent data from clinical
trials regarding the use of PARP inhibitor mono- and combination
therapy
-
Incorporate evidence-based
benefit-risk assessment and utilize shared decision-making in
the development of individualized treatment plans
-
Assess managed care considerations
to facilitate optimal use of novel combination options,
including PARP inhibitors, in prostate cancer
|
Faculty: |
Matthew R. Smith, M.D.,
Ph.D.
Professor of Medicine, Harvard Medical School
Director, MGH Genitourinary Malignancies Program |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Smith has served as a consultant for Astellas,
Bayer, Janssen, Lilly, and Pfizer. He has received
grant/research support from Bayer, Janssen, and Lilly.
His presentation has been reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
AstraZeneca, Merck Sharp & Dohme LLC, and Sanofi
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |